Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - Time to Buy?

Key Points

• Telix Pharmaceuticals (NASDAQ: TLX) experienced a 2% increase in trading volume, with 36,707 shares traded, though the stock price fell to $12.02 from a previous close of $12.26.
• Wall Street analysts have given positive outlooks for Telix, with target prices set at $22.00 by Wedbush and $23.00 by HC Wainwright, both suggesting potential for growth.
• Several hedge funds have increased their stakes in Telix Pharmaceuticals during the second quarter, including Pier Capital LLC, which acquired a stake worth approximately $3 million.

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 36,707 shares traded hands during mid-day trading, an increase of 2% from the previous session's volume of 35,954 shares.The stock last traded at $12.02 and had previously closed at $12.26.

Analyst Ratings Changes

TLX has been the topic of several research analyst reports. Wedbush restated an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th. HC Wainwright initiated coverage on shares of Telix Pharmaceuticals in a research report on Thursday, July 3rd. They set a "buy" rating and a $23.00 price target on the stock. Finally, William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th.

Telix Pharmaceuticals Trading Down 3.7%

The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78. The business's 50-day simple moving average is $15.59 and its 200 day simple moving average is $16.74.

Institutional Trading of Telix Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Pier Capital LLC purchased a new stake in shares of Telix Pharmaceuticals during the second quarter valued at approximately $3,037,000. ABC Arbitrage SA purchased a new stake in Telix Pharmaceuticals in the first quarter worth $451,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Telix Pharmaceuticals in the second quarter worth $297,000. Blair William & Co. IL purchased a new stake in Telix Pharmaceuticals in the second quarter worth $217,000. Finally, Private Advisor Group LLC purchased a new stake in Telix Pharmaceuticals in the first quarter worth $170,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.